Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov10510.25208/0042-4609-2015-91-1-54-61ORIGINAL STUDIESНАУЧНЫЕ ИССЛЕДОВАНИЯPersonalization of an anti-cytokine therapy of psoriatic patientsПерсонализация антицитокиновои терапии больных псориазомKubanovA. A.КубановА. А.
Russian Federation
SvishchenkoS. I.СвищенкоС. И.
Russian Federation
svischenko@cnikvi.ruState Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian FederationФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России24022015911546124082017Copyright ©; 2015, Kubanov A.A., Svishchenko S.I.Copyright ©; 2015, Кубанов А.А., Свищенко С.И.2015Kubanov A.A., Svishchenko S.I.Кубанов А.А., Свищенко С.И.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/105

Goal. To develop a personalized approach to the administration of an anti-cytokine therapy to patients suffering from moderate to severe and severe forms of psoriasis based on clinical and immunological parameters. Materials and methods. The authors treated 79 patients suffering from moderate to severe and severe forms of psoriasis vulgaris using anti-cytokine drugs; they assessed the clinical efficacy of the therapy taking into account changes in the PASI index and assessed the levels of cytokines (IL-4, IL-6, IL-17, TNF-α, IL-20, IL-22, IL-31, IL-12, IL-11, IL-18), intercellular adhesion molecules, vascular endothelial growth factor (ICAM-1,VEGF) in the blood serum of patients prior to and in the process of treatment. Results. The authors determined the criteria for a personalized approach to the administration of anti-cytokine drugs.

Цель. Разработка персонализированного подхода к назначению антицитокиновой терапии больным со среднетяжелыми и тяжелыми формами псориаза на основании клинико-иммунологических показателей. Материал и методы. Проведено лечение 79 больных со среднетяжелыми и тяжелыми формами вульгарного псориаза антицитокиновыми препаратами; дана оценка клинической эффективности терапии с учетом динамики индекса PASI, изучен уровень цитокинов (IL-4, 6, 17, TNF-α, IL-20, 22, 31, 12, 11, 18), молекул межклеточной адгезии, фактора роста сосудистого эндотелия в сыворотке крови больных до и в процессе лечения. Результаты. Определены критерии персонализированного подхода к назначению антицитокиновых препаратов.

псориазадалимумаб (хумира)инфликсимаб (ремикейд)устекинумаб (стелара!антицитокиновые препаратыперсонализацияpsoriasisAdalimumab (Humira)Infliximab (Remicade)Ustekinumab (Stelara)anti-cytokine drugspersonalizationJain K.K. Personalized Medicine. Waltham: Decision Resources Inc. 1998.Antoni C., Manger B. Infliximab for psoriasis and psoriatic arthritis Clin.Exp. Rheumatol 2002; 20: 122-125.Lee E., Trepicchio W., Oestreicher J.L. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med 2004; 199: 125-130.Watanabe H. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J. Invest. Dermatol 2009; 129: 650-656. Вестник дерматологии и венерологии Научные исследования л 61Znamenskaya L.F., Frigo N.V, Rotanov S.V, Volkov I.A, Volnukhin V.A., Zhilova M.B. Personalized approach to the selection of therapy for patients with psoriasis based on the results of molecular and genetic tests. Vestn Dermatol Venerol 2010; 5: 77-83.Korotaeva T.V. Adalimumab v lechenii psoriaticheskogo artrita. Dermatologija. Prilozhenie k zhurnalu CONSILIUM MEDICUM 2013; 1: 21-27. [Коротаева Т.В. Адалимумаб в лечении псориатического артрита. Дерматология. Приложение к журналу CONSlLlUM MEDICUM 2013; 1: 21-27.]Kubanov A.A., Matushevskaya YU.I. Experience of application of infliximab in treatment of patients suffering from severe forms of psoriasis Vestn Dermatol Venerol 2008; 6: 81-86.Antoni C., Krueger G. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis 2005; 64: 1150-1157.Chaudhari U., Romano P. et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.Feldman S., Gordon K. et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005; 152: 954-960.Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.Gottlieb A.B, Evans R. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-1204.Gordon K.B., Langley R.G, Leopardi C. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.Menter A., Tyring SK, Gordon K. et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.Menter A., Tyring S., Gordon K. et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III train. J Am Acad Dermatol 2008; 58 (1): 106-115.Gottlieb A., Menter A., Mendelsohn A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373 (9664): 633-640.Griffiths C.E.M., Strober B. et al. Comparison of ustekinumab and etanercept for moderateto-severe psoriasis N Engl J Med 2010; 362: 118-128.Krueger G.G., Langley R.G., Leonardi C. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med Feb 8 2007; 56 (6): 580-592.Leonardi C.L., Kimball A.B., Papp K.A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. May 17 2008; 371 (9625): 1665-1674.Wittig B. Drug evaluation: CnTo-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Current opinion in investigational drugs (London, England: 2000) 2007; 8: 947.Balding J., Kane D., Livingstone W. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003; 48 (5): 1408-13.Gedebjerg A., Johansen C. еt al. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta dermato-venereologica 2013; 93 (2): 150-5.